article pub. Aug 4, 2026
Health Affairs Forefront analysis by Mengyuan Fu, Joseph S. Ross, Ngoc-Trang Adrienne H. Nguyen, and Reshma Ramachandran of the FDA Pharmacy Compounding Advisory Committee's July 2026 vote to add six unapproved peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the 503A Bulks List despite FDA scientists finding insufficient evidence of benefit, safety, or manufacturing quality, and documents financial conflicts of interest among the voting committee members.